From the Research
Yes, lanreotide is available in Japan, as evidenced by a study published in 2013 1, which demonstrated its efficacy and safety in Japanese patients with acromegaly or pituitary gigantism.
Key Points
- Lanreotide is marketed under the brand name Somatuline Autogel and is approved for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome.
- In Japan, lanreotide is typically administered as a deep subcutaneous injection, with dosages ranging from 60 mg to 120 mg given every 4 weeks, depending on the condition being treated and the patient's response.
- The medication is supplied in pre-filled syringes for ease of administration.
- Patients should be aware that treatment is typically long-term and requires regular monitoring of symptoms and hormone levels to assess efficacy.
- Lanreotide works by mimicking the action of somatostatin, a natural hormone that inhibits the release of growth hormone and various other hormones, making it effective for conditions characterized by excessive hormone production.
- Common side effects include injection site reactions, gastrointestinal disturbances, and gallstone formation, so regular medical follow-up is important.
Evidence
The study published in 2013 1 demonstrated that lanreotide Autogel provided early and sustained control of elevated GH and IGF-I levels, improved acromegaly symptoms, and was well tolerated in Japanese patients with acromegaly or pituitary gigantism. Another study published in 2016 2 summarized the development of lanreotide and its role in treating gastroenteropancreatic neuroendocrine tumors, highlighting its ability to prevent tumor progression and improve symptoms.
Administration and Monitoring
Lanreotide should be administered by a healthcare professional, and patients should be closely monitored for signs of efficacy and potential side effects. Regular monitoring of symptoms and hormone levels is crucial to assess the effectiveness of treatment and adjust dosages as needed.